Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free » The story of Eli ...

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...

We recently compiled a list of the 16 Best Income Stocks To Buy According to Analysts. In this article, we are going to take ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 491.86% and ...

At least 29 patent suits were filed in the District of New Jersey in November, reflecting a jump from the rate of 18 suits ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Stock Editorial via Getty Images An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has ...

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...